LYMPHOPLASMACYTIC LYMPHOMA

This phase II trial is testing whether a combination of venetoclax and rituximab works better than current standard treatments (ibrutinib plus rituximab or zanubrutinib alone) for people with previously untreated Waldenstrom's macroglobulinemia, a rare type of blood cancer. The s…

This early-stage trial is testing a new drug called MK-1045 (CN201) in about 100 people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to treatment. MK-1045 is an immunotherapy designed to help the immune system fight the cancer. The main goals are to check …

This Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of…

This early-phase trial is testing a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells. It is for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. The main go…

This phase 2 study is testing a time-limited combination of three drugs—pirtobrutinib, venetoclax, and rituximab—in 40 patients newly diagnosed with Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this regimen can achieve a very good partial response o…

This study tests a cancer pill called venetoclax in 14 Japanese adults with a rare blood cancer (Waldenström macroglobulinemia) that has come back or not responded to treatment. Participants take the drug by mouth daily, with doses slowly increased. The main goal is to see how ma…

This study tests a stem cell transplant from half-matched (haploidentical) donors for people with various blood cancers. Before the transplant, patients receive chemotherapy and low-dose radiation to prepare their body. The goal is to replace diseased bone marrow with healthy don…

This study tests an experimental drug called MDX2003 in 180 adults with B-cell lymphomas (like diffuse large B-cell lymphoma or follicular lymphoma) that have returned or stopped responding to at least two prior treatments. The main goals are to find the safest dose and check if …

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…

This phase 2 trial is testing a combination of two drugs, acalabrutinib and obinutuzumab, in people with untreated follicular lymphoma or other slow-growing non-Hodgkin lymphomas. The goal is to see if this drug pair can shrink tumors and control the disease. About 49 participant…

This early-phase study is testing a new drug called YK012 in 48 adults with relapsed or refractory B-cell non-Hodgkin lymphoma. YK012 is a bispecific antibody designed to help the body's immune T cells recognize and kill cancer B cells. The main goals are to check the drug's safe…

This study tests a new type of CAR-T cell therapy that uses mRNA to target two proteins (CD19 and CD20) on cancer cells. It is for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The goal is to see if it is safe and effective, with up to …

This study tests whether the drug pacritinib is safe and effective for adults with Waldenström macroglobulinemia, a rare blood cancer, when previous treatments have stopped working. About 30 participants will receive pacritinib and be monitored for tumor shrinkage and side effect…

This early-stage study is testing a new oral drug called ZE50-0134 in 66 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or certain low-grade lymphomas that have come back or not responded to prior treatments. The main goal is to check the drug's…

This early-stage study tests an experimental drug called ICP-248, taken as a pill, for people with certain blood cancers (like leukemia or lymphoma). The drug is given alone or with another drug, orelabrutinib. The main goals are to check safety, find the right dose, and see if i…

This early-phase trial is testing a new radioactive imaging agent called 64Cu-LLP2A to see if it can safely and clearly show blood cancers like multiple myeloma and lymphoma on PET/CT scans. The study includes healthy volunteers and patients with these cancers, including those wh…

This study tests a personalized program combining exercise and nutrition advice to help reduce fatigue in people with indolent (slow-growing) lymphomas, such as chronic lymphocytic leukemia and follicular lymphoma. Participants receive an individualized exercise plan and dietary …

This study follows up to 1,000 adults with certain slow-growing blood cancers (CLL, SLL, LPL, WM) to track how the diseases change over time. Participants have regular check-ups and blood draws every 6 to 24 months, and may also have optional biopsies or scans for research. No tr…

This study follows 150 adults aged 70 and older with low-grade non-Hodgkin lymphoma to see how their quality of life changes during treatment. Researchers will use questionnaires to track well-being from diagnosis through one year after therapy starts. The goal is to identify whi…